Physiologically based pharmacokinetic modeling of arsenic in the mouse

Journal of Toxicology and Environmental Health - Part A

Volumn 67, Issue 1, 2004, Pages 43-71

  Robinan Gentry, P ^a   Covington, Tammie R ^a   Mann, Sabine ^b   Shipp, Annette M ^a   Yager, Janice W ^c   Clewell, Harvey J ^a  

^a ENVIRON INTERNATIONAL CORPORATION   (United States)

^b EPRI ^*  (Switzerland)

^c ELECTRIC POWER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC ACID; ARSENIC TRIOXIDE; CACODYLIC ACID; CARCINOGEN; INORGANIC COMPOUND; METHANEARSONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DOSIMETRY; EXPERIMENTAL MODEL; FEMALE; HAMSTER; LONG TERM EXPOSURE; MALE; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE LEVEL; TOXICITY TESTING; TOXICOKINETICS; VALIDATION PROCESS;

ANIMALIA; CRICETINAE;

EID: 1642503825     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390490253660     Document Type: Article

References (34)

1. Baker, H., Lindsey, J., and Weisbroth, S. 1979. The laboratory rat: Volume I—Biology and diseases.San Diego, CA: Academic Press.
2. Bernstam, L., and Nriagu, J. 2000. Molecular aspects of arsenic stress. J. Toxicol. Environ. Health B3:293-322.
3. Brown, R., Delp, M., Lindstedt, S., Rhomberg, L., and Beliles, R. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind. Health13:407-484.
4. Chen, C., and Lin, L. 1994. Human carcinogenicity and atherogenicity induced by chronic exposure to inorganic arsenic. In Arsenic in the environment. Part II: Human health and ecosystem effects, ed. J. O. Nriagu, pp. 109-131. New York: John Wiley & Sons.
5. Clewell, H., Barton, H., Gentry, P., Shipp, A., Yager, J., and Andersen, M. 1998. Requirements for a biologically realistic arsenic risk assessment. Int. J. Toxicol.18:131-147.
6. DelRazo, L., Styblo, M., and Thomas, D. 2000. Determination of trivalent methylated arsenic species in water, cultured rat hepatocytes, and human urine.Fourth International Conference on Arsenic Exposure and Health Effects, Poster 10.
7. Easterling, M., Stylbo, M., Evans, M., and Kenyon, E. 2002. Pharmacokinetic modeling of arsenite uptake and metabolism in hepatocytes: Mechanistic insights and implications for further experiments. J. Phar-macokinet. Pharmacodyn.29:207-233.
8. Golub, M. S., Macintosh, M. S., and Baumrind, N. 1998. Developmental and reproductive toxicity of inorganic arsenic: Animal studies and human concerns. J. Toxicol. Environ. Health B1:199-241.
9. Hall, L., George, S., Kohan, M., Stylbo, M., and Thomas, D. 1997. In vitro methylation of inorganic arsenic on mouse intestinal cecum. Toxicol. Appl. Pharmacol.148:101-109.
10. Healy, S., Casarez, E., Ayala-Fierro, F., and Aposhian, H. 1998. Enzymatic methylation of arsenic compounds. V. Arsenite methyltransferase activity in tissues of mice. Toxicol. Appl. Pharmacol.148:65-70.
11. Hsueh, Y.-M., Huang, Y.-L., Huang, C.-C., Wu, W.-L., Chen, H.-M., Yang, M.-H., Lue, L.-C., and Chen, C.-J. 1998. Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J. Toxicol. Environ. Health A54:431-444.
12. Hughes, M., and Kenyon, E. 1998. Dose-dependent effects on the disposition of monomethylarsonic acid and dimethylarsenic acid in the mouse after intravenous administration. J. Toxicol. Environ. Health A53:95-112.
13. Hughes, M., Kenyon, E., Edwards, B., Mitchell, C., and Thomas, D. 1999. Strain-dependent disposition of inorganic arsenic in the mouse. Toxicology137:95-108.
14. Hughes, M., Menache, M., and Thompson, D. 1994. Dose-dependent disposition of sodium arsenate in mice following acute oral exposure. Fundam. Appl. Toxicol.22:80-89.
15. Kanisawa, M., and Schroeder, H. 1967. Life term studies on the effects of arsenic, germanium, tin, and vanadium on spontaneous tumors in mice. Cancer Res.27:1192-1195.
16. Kenyon, E., Fea, M., Styblo, M., and Evans, M. 2001. Application of modelling techniques to the planning of in vitro arsenic kinetic studies. ATLA29:15-33.
17. Kenyon, E., Hughes, M., and Levander, O. 1997. Influence of dietary selenium on the disposition of arsenate in the female B6C3F1 mouse. J. Toxicol. Eviron. Health51:279-299.
18. King, F., Dedrick, R., Collins, J., Matthews, H., and Birnbaum, L. 1983. Physiological model for the pharmacokinetics of 2,3,7,8-tetrachlorodibenzofuran in several species. Toxicol. Appl. Pharmacol.67:392-400.
19. Kitchin, K. 2001. Recent advances in arsenic carcinogenesis: Modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol.172:249-261.
20. Le, X., Lu, X., Ma, M., Cullen, W., Aposhian, H., and Zheng, B. 2000. Speciation of key arsenic metabolic intermediates in human urine. Anal. Chem.72:5172-5177.
21. Lubin, J., Pottern, L., Stone, B., and Fraumeni, J. 2000. Respiratory cancer in a cohort of copper smelter workers: Results from more than 50 years of follow-up. Am. J. Epidemiol.151:554-565.
22. Mann, S., Droz, P., and Vahter, M. 1996a. A physiologically based pharmacokinetic model for arsenic exposure: I. Development in hamsters and rabbits. Toxicol. Appl. Pharmacol.136:8-22.
23. Mann, S., Droz, P., and Vahter, M. 1996b. A physiologically based pharmaokinetic model for arsenic exposure: II. Validation and application in humans. Toxicol. Appl. Pharmacol. 140:471-486.
24. Mass, M. 1998. Wild type and p53 deficient mice exposed to arsenical compounds. EPA Study Number 97-05.
25. Moser, G., Goldsworthy, T., and Tice, R. 2000. Sodium arsenite studies in p53 +/- Mice. Denver, CO; AWWA Research Foundation and the American Water Works Association.
26. Ng, J., Seawright, S., Wi, L., Garnett, C., Cirswell, B., and Moore, M. 1999. Tumours in mice induced by exposure to sodium arsenate in drinking water. Arsenic exposure and health effects, eds. W. Chappell, C. Abernathy, and R. Calderon, pp. 217-223. Elsevier.
27. Sampayo-Reyes, A., Zakharyan, R., Healy, S., and Aposhian, H. 2000. Monomethylarsonic acid reductase and monomethyarsonous acid in hamster tissue. Chem. Res. Toxicol.13:1181-1186.
28. Tsai, S.-M., Wang, T.-N., and Ko, Y.-C. 1998. Cancer mortality trends in a Blackfoot disease endemic community of Taiwan following water source replacement. J. Toxicol. Environ. Health A55:389-404.
29. Vega, L., Styblo, M., Patterson, R., Cullen, W., Wang, C., and Germolec, D. 2001. Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol. Appl. Pharmacol. 172:225-232.
30. Waalkes, M., Keefer, L., and Diwan, B. 2000. Induction of proliferative lesions of the uterus, testes, and liver in Swiss mice given repeated injections of sodium arsenate: Possible estrogenic mode of action. Toxicol. Appl. Pharmacol. 166:24-35.
31. Wang, Z., Dey, S., Rosen, B., and Rossman, T. 1996. Efflux-mediated resistance to arsenicals in arsenic-resistant and -hypersensitive Chinese hamster cells. Toxicol. Appl. Pharmacol.137:112-119.
32. Yu, D. 1999. A pharmacokinetic modeling of inorganic arsenic: A short-term oral exposure model for humans. Chemosphere.39:2737-2747.
33. Yu, R., Hsu, K., Chen, C., and Froines, J. 2000. Arsenic methylation capacity and skin cancer. Cancer Epidemiol. Biomarkers9:1259-1262.
34. Zakharyan, R., Wu, Y., Bogdan, G., and Aposhian, H. 1995. Enzymatic methylation of arsenic compounds: Assay, partial purification, and properties of arsenite methyltransferase and monomethylarsonic acid methyltransferase of rabbit liver. Chem. Res. Toxicol.8:1029-1038.